Moving forward with reactive oxygen species involvement in antimicrobial lethality

Xilin Zhao1–3, Yuzhi Hong1 and Karl Drlica1,2*

1Public Health Research Institute, New Jersey Medical School, Rutgers Biomedical and Health Sciences, 225 Warren Street, Newark, NJ 07103, USA; 2Department of Microbiology and Molecular Genetics, New Jersey Medical School, Rutgers Biomedical and Health Sciences, 225 Warren Street, Newark, NJ 07103, USA; 3State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, South Xiang-An Road, Xiang-An District, Xiamen, Fujian Province 361102, China

*Corresponding author. Tel: +917-821-6847; Fax: +973-854-3101; E-mail: drlicaka@njms.rutgers.edu

Support for the contribution of reactive oxygen species (ROS) to antimicrobial lethality has been refined and strengthened. Killing by diverse antimicrobials is enhanced by defects in genes that protect against ROS, inhibited by compounds that block hydroxyl radical accumulation, and is associated with surges in intracellular ROS. Moreover, support has emerged for a genetic pathway that controls the level of ROS. Since some antimicrobials kill in the absence of ROS, ROS must add to, rather than replace, known killing mechanisms. New work has addressed many of the questions concerning the specificity of dyes used to detect intracellular ROS and the specificity of perturbations that influence ROS surges. However, complexities associated with killing under anaerobic conditions remain to be resolved. Distinctions among primary lesion formation, resistance, direct lesion-mediated killing and a self-destructive stress response are discussed to facilitate efforts to potentiate ROS-mediated bacterial killing and improve antimicrobial efficacy.

Keywords: ROS, antibiotics, killing, post-damage cellular response

Reactive oxygen species (ROS) involvement in antimicrobial action

In 2007 Kohanski et al.1 proposed that ROS (superoxide, peroxide and hydroxyl radicals) contribute to lethality for fluoroquinolones, β-lactams and aminoglycosides. The work explained why antioxidants suppress quinolone-mediated mutagenesis2 and why oxidative stress is detected in bacteria treated with antimicrobials.3,4 Follow-up work showed that the deletion of genes encoding catalase/peroxidase increases lethality for the three antibiotic classes,5 and upstream genes appeared to be part of a death pathway.6–10 Moreover, the contribution of DNA repair genes to killing by ampicillin and kanamycin was explained as a consequence of ROS-mediated DNA damage.11 Stress-induced, ROS-mediated bacterial self-destruction opened new avenues for antimicrobial enhancement with the clear understanding that the contribution of ROS to antimicrobial killing is complex—ROS adds to, but does not replace, previously established killing mechanisms specific to each compound class.12 The level of ROS contribution to antimicrobial killing depends on compound type and drug exposure. Indeed, some quinolones rely fully on ROS for rapid killing, while others do not.13,14

Contrary opinions on the ROS hypothesis

In 2013 four reports addressed aspects of the ROS hypothesis. One contrary view actually confirmed that some antimicrobials kill in the absence of ROS15 using norfloxacin, a quinolone known to kill *Escherichia coli* by an ROS-dependent mechanism at low concentrations and an ROS-independent mechanism at high concentrations.13 As expected, thiourea and anaerobic conditions interfered with norfloxacin-mediated killing at low but not high concentrations.15 Ofloxacin, a more potent fluoroquinolone, was affected little by anoxia, as expected for a compound that kills largely by the ROS-independent pathway. This behaviour of quinolones is described in Figure 1: killing can derive directly from the primary lesion or from an ROS-mediated stress response. For ampicillin and kanamycin, the absence of AhpCF peroxidase was reported to enhance activity,5 but activity was still seen with ampicillin when experiments were conducted in an anaerobic chamber.15 These observations suggest that ampicillin has a mode of killing that does not involve ROS.

A second report16 raised issues concerning chemical probes of ROS effects. For example, off-target effects are difficult to rule out for antioxidants and iron chelators, compounds widely used to correlate ROS with antimicrobial-mediated killing. Questions were also raised about the specificity of dyes used to assess ROS surges associated with killing. As mentioned above,15 some agents (ampicillin and norfloxacin) were lethal when *E. coli* was treated in an anaerobic chamber. These data are consistent with some killing being ROS-independent. In these experiments ambiguity was introduced by plating in air following anoxic antimicrobial treatment, a procedure that may affect bacterial survival.17
Many of the objections to the ROS–antimicrobial lethality hypothesis were subsequently addressed experimentally and in reviews. For example, dye specificity for intracellular ROS detection was addressed by examining seven different dyes acting through a variety of chemistries. Norfloxacin, ampicillin and gentamicin did indeed differ in the level of response elicited, but lethal antimicrobials generally elevated ROS levels. In another example, an intracellular assay for peroxide revealed an increase in ROS associated with antibiotic treatment, a result not seen with an extracellular assay. Moreover, an Hpx catalase/peroxidase triple mutant (katG, katE, ahpCF) was found to constitutively express factors expected to protect from oxidative stress. This observation explained a previous failure to observe elevated antimicrobial lethality with this mutant. As additional evidence, a variety of superoxide- and peroxide-sensitive promoters were activated by norfloxacin and ampicillin. Finally, overexpression of katG reduced antibiotic-mediated lethality, thereby complementing earlier work in which the deletion of catalase/peroxidase genes increased lethality.

While the role of ROS in antimicrobial-mediated killing is imperfectly understood, the recent follow-up work forces us to consider whether antioxidant consumption is advisable during antibiotic therapy, since it appears to affect antibiotic action. These observations also encourage work to find enhancers of ROS-mediated antimicrobial lethality. To facilitate that effort, we briefly consider measurements of lethal stress responses.

### Assays for factors involved in lethal stress responses

Distinguishing between bacteriostatic and bactericidal activity is a key issue. Bacteriostatic action, which is associated with primary lesion formation, is usually measured as MIC or efficiency of plating, parameters that reflect drug uptake, efflux and drug-target affinity; high MIC values are associated with resistance. These parameters are not designed to measure killing. (b) Primary damage stimulates a pathway that leads to ROS accumulation. This pathway can be blocked by treating cells with iron chelators and antioxidants; it is stimulated by deficiencies in catalase/peroxidases. (c) ROS cause secondary damage to nucleic acids, proteins and lipids. (d) Secondary damage stimulates additional ROS production. When secondary damage exceeds a critical threshold, it becomes self-amplifying. (e) Self-amplification of ROS assures cell death. (f) If primary damage is severe enough, it can result in death directly, i.e. without the need for ROS even though ROS accumulate. Killing due to primary damage can be measured by blocking the accumulation of ROS. To study factors specifically involved in death rather than primary lesion formation, factors influencing step (a) (e.g. drug uptake, efflux and target affinity) need to be eliminated from consideration. This elimination can be achieved by normalizing drug concentration to MIC when survival is measured. Rapid killing may require drug concentrations above MIC, as seen for quinolones. Not shown are ROS-mediated effects on drug uptake and efflux and on feedback regulatory loops controlling ROS.

Two other reports emphasize the utility of Figure 1. One defines features that affect gentamicin uptake and therefore primary lesion formation and direct killing. Such experiments cannot distinguish effects on growth inhibition (MIC) from killing, nor can they separate antimicrobial-specific mechanisms of killing from a secondary, lethal stress response common to multiple antimicrobials. The other report used an assay, efficiency of plating, that measures primary lesion formation and resistance, not killing. Thus, neither report specifically addressed ROS-mediated killing.

In summary, the follow-up work confirmed that ROS does not replace known lethal mechanisms and emphasized that killing under anaerobic conditions is far from understood. Apparent weaknesses in the support for ROS being an additional killing mechanism do not allow the hypothesis to be rejected. Nevertheless, a set of commentaries has emerged, revealing a need for clarification and another round of experimentation.
Concluding remarks

We conclude that ROS contribute to the lethal action of many antimicrobials. Exceptions deepen our understanding of antimicrobials, and apparent paradoxes promise new insights. For example, the MazF toxin is proposed to be part of the pathway that communicates information about antimicrobial-mediated lesions to the respiratory chain for ROS production. Why do some laboratories conclude that the MazF toxin is protective while others conclude the opposite? Why do subinhibitory doses of a superoxide generator protect E. coli from some types of antimicrobial-mediated killing, while high doses of the generator enhance lethality? It appears that bacteria contain a set of bifunctional factors that allow cells to make a live-or-die decision based on whether the stress-mediated damage is repairable. Since the cost of double-strand DNA break repair can be high, bacterial populations may use ROS-mediated cell death to maximize resource utilization. Perhaps we can exploit this feature to help control infections.

Acknowledgements

We thank Arnold Bendich and Marila Gennaro for critical comments on the manuscript prior to submission.

Funding

The authors’ work was supported by NIH grants 1DP2OD007423, 2R01AI073491 and 1R21AI103781.

Transparency declarations

None to declare.

References

22 Hadlington S. Battleground develops over antibiotic killing mechanism. ChemistryWorld, 8 March 2013.


